|
|
1Z105 |
|
Vaxjo ID |
489 |
|
Vaccine Adjuvant Name |
1Z105 |
|
Adjuvant VO ID |
VO_0005766
|
|
Description |
synthetic TLR4 agonist that induces Th2 response |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Structure |
substituted pyrimido[5,4-b]indole |
|
Function |
Type: TLR agonist vaccine adjuvant. Target Receptor: Toll-like receptor 4 (TLR4). Induces Th2-biased immune profile. enhanced antigen presentation of dendritic cells via TLR4 activation |
|
Safety |
less reactogenic than a squalene-based adjuvant, AddaVax |
| References |
Goff et al., 2015: Goff PH, Hayashi T, Martínez-Gil L, Corr M, Crain B, Yao S, Cottam HB, Chan M, Ramos I, Eggink D, Heshmati M, Krammer F, Messer K, Pu M, Fernandez-Sesma A, Palese P, Carson DA. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. Journal of virology. 2015; 89(6); 3221-3235. [PubMed: 25568203].
|
|
